ALACHUA, FL – January 9, 2014 – AxoGen, Inc. (NASDAQ: AXGN), the only regenerative medicine company completely focused on peripheral nerve repair, today announced that it will sponsor a lunch symposium and panel discussion at the combined annual meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN) and American Society for Reconstructive Microsurgery (ASRM) taking place January 8-14, 2014 in Kauai, Hawaii. The symposium and discussion will focus on improving outcomes including a review of the latest clinical evidence and the principles of nerve repair. The symposium will feature presentations by a panel of renowned leaders in the nerve repair space including, Peter J. Evans, MD, PhD, FRCSC, The Cleveland Clinic; Jonathan Isaacs, MD, Virginia Commonwealth University; Bauback Safa, MD, MBA, FACS, The Buncke Clinic in San Francisco, CA and Erick DeVinney of AxoGen.
Presentation Title: Current Concepts for Improving Nerve Repair Outcomes
Date/Time: Thursday, January 9, 2014: 1:00 – 2:30 p.m. HST
Location: Ballroom III (Grand Hyatt Kauai)
Erick DeVinney, AxoGen’s newly appointed Vice President of Clinical and Translational Sciences, said, “Since hand injuries can often result in damaged peripheral nerves, there is a need for surgeons to understand the current and forward-thinking scientific concepts for reconstructing these nerves with optimal patient outcomes. AxoGen is looking forward to bringing together leading surgeons in the field at the combined annual meeting and discussing options for improving nerve repair.”
AxoGen will also be exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 4 throughout the entire combined conference and will provide surgeons with the opportunity to interact with the products in a bench top model.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a regenerative medicine company based in Alachua, Florida. Founded in 2002, AxoGen is the only company to completely focus on peripheral nerve repair. AxoGen’s portfolio of products are available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
AxoGen, Inc.
Greg Freitag, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com
www.AxoGenInc.com
Help employers find you! Check out all the jobs and post your resume.
